Literature DB >> 25477207

An Env-derived multi-epitope HIV chimeric protein produced in the moss Physcomitrella patens is immunogenic in mice.

Lucía Orellana-Escobedo1, Sergio Rosales-Mendoza, Andrea Romero-Maldonado, Juliana Parsons, Eva L Decker, Elizabeth Monreal-Escalante, Leticia Moreno-Fierros, Ralf Reski.   

Abstract

KEY MESSAGE: The first report on the recombinant production of a candidate vaccine in the moss system. The need for economical and efficient platforms for vaccine production demands the exploration of emerging host organisms. In this study, the production of an antigenic protein is reported employing the moss Physcomitrella patens as an expression host. A multi-epitope protein from the Human Immunodeficiency Virus (HIV) based on epitopes from gp120 and gp41 was designed as a candidate subunit vaccine and named poly-HIV. Transgenic moss plants were generated carrying the corresponding poly-HIV transgene under a novel moss promoter and subsequently seven positive lines were confirmed by PCR. The poly-HIV protein accumulated up to 3.7 µg g(-1) fresh weight in protonema cultures. Antigenic and immunogenic properties of the moss-produced recombinant poly-HIV are evidenced by Western blots and by mice immunization assays. The elicitation of specific antibodies in mice was observed, reflecting the immunogenic potential of this moss-derived HIV antigen. This is the first report on the production of a potential vaccine in the moss system and opens the avenue for glycoengineering approaches for the production of HIV human-like glycosylated antigens as well as other vaccine prototypes under GMP conditions in moss bioreactors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25477207     DOI: 10.1007/s00299-014-1720-6

Source DB:  PubMed          Journal:  Plant Cell Rep        ISSN: 0721-7714            Impact factor:   4.570


  43 in total

1.  Moss-based production of asialo-erythropoietin devoid of Lewis A and other plant-typical carbohydrate determinants.

Authors:  Juliana Parsons; Friedrich Altmann; Claudia K Arrenberg; Anna Koprivova; Anna K Beike; Christian Stemmer; Gilbert Gorr; Ralf Reski; Eva L Decker
Journal:  Plant Biotechnol J       Date:  2012-05-24       Impact factor: 9.803

2.  Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates.

Authors:  Barton F Haynes; Benjiang Ma; David C Montefiori; Terri Wrin; Christos J Petropoulos; Laura L Sutherland; Richard M Scearce; Cathrine Denton; Shi-Mao Xia; Bette T Korber; Hua-Xin Liao
Journal:  Virology       Date:  2005-10-20       Impact factor: 3.616

3.  Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope.

Authors:  Susan Zolla-Pazner; Sandra Sharpe Cohen; Chavdar Krachmarov; Shixia Wang; Abraham Pinter; Shan Lu
Journal:  Virology       Date:  2007-12-03       Impact factor: 3.616

Review 4.  Glycoprotein production in moss bioreactors.

Authors:  Eva L Decker; Ralf Reski
Journal:  Plant Cell Rep       Date:  2011-09-29       Impact factor: 4.570

5.  Glyco-engineering of moss lacking plant-specific sugar residues.

Authors:  C M Huether; O Lienhart; A Baur; C Stemmer; G Gorr; R Reski; E L Decker
Journal:  Plant Biol (Stuttg)       Date:  2005-05       Impact factor: 3.081

6.  Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope.

Authors:  N L Letvin; S Robinson; D Rohne; M K Axthelm; J W Fanton; M Bilska; T J Palker; H X Liao; B F Haynes; D C Montefiori
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

7.  Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity.

Authors:  Barney S Graham; M Juliana McElrath; Michael C Keefer; Kyle Rybczyk; David Berger; Kent J Weinhold; Janet Ottinger; Guido Ferarri; David C Montefiori; Don Stablein; Carol Smith; Richard Ginsberg; John Eldridge; Ann Duerr; Pat Fast; Barton F Haynes
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

8.  Preferential expression and immunogenicity of HIV-1 Tat fusion protein expressed in tomato plant.

Authors:  Marni E Cueno; Yurina Hibi; Katsuo Karamatsu; Yasuhiro Yasutomi; Kenichi Imai; Antonio C Laurena; Takashi Okamoto
Journal:  Transgenic Res       Date:  2010-01-14       Impact factor: 2.788

9.  In vivo glyco-engineered antibody with improved lytic potential produced by an innovative non-mammalian expression system.

Authors:  Manfred Schuster; Wolfgang Jost; Geert C Mudde; Susanne Wiederkum; Cornelia Schwager; Evelyne Janzek; Friedrich Altmann; Johannes Stadlmann; Christian Stemmer; Gilbert Gorr
Journal:  Biotechnol J       Date:  2007-06       Impact factor: 4.677

10.  An improved and highly standardised transformation procedure allows efficient production of single and multiple targeted gene-knockouts in a moss, Physcomitrella patens.

Authors:  Annette Hohe; Tanja Egener; Jan M Lucht; Hauke Holtorf; Christina Reinhard; Gabriele Schween; Ralf Reski
Journal:  Curr Genet       Date:  2003-10-29       Impact factor: 3.886

View more
  11 in total

Review 1.  Current Developments and Future Prospects for Plant-Made Biopharmaceuticals Against Rabies.

Authors:  Sergio Rosales-Mendoza
Journal:  Mol Biotechnol       Date:  2015-10       Impact factor: 2.695

2.  Chlamydomonas reinhardtii chloroplasts express an orally immunogenic protein targeting the p210 epitope implicated in atherosclerosis immunotherapies.

Authors:  Josué I Beltrán-López; Andrea Romero-Maldonado; Elizabeth Monreal-Escalante; Bernardo Bañuelos-Hernández; Luz Mt Paz-Maldonado; Sergio Rosales-Mendoza
Journal:  Plant Cell Rep       Date:  2016-02-17       Impact factor: 4.570

Review 3.  Physcomitrella patens, a versatile synthetic biology chassis.

Authors:  Ralf Reski; Hansol Bae; Henrik Toft Simonsen
Journal:  Plant Cell Rep       Date:  2018-05-24       Impact factor: 4.570

Review 4.  Moss-made pharmaceuticals: from bench to bedside.

Authors:  Ralf Reski; Juliana Parsons; Eva L Decker
Journal:  Plant Biotechnol J       Date:  2015-05-25       Impact factor: 9.803

Review 5.  Algal Cell Factories: Approaches, Applications, and Potentials.

Authors:  Weiqi Fu; Amphun Chaiboonchoe; Basel Khraiwesh; David R Nelson; Dina Al-Khairy; Alexandra Mystikou; Amnah Alzahmi; Kourosh Salehi-Ashtiani
Journal:  Mar Drugs       Date:  2016-12-13       Impact factor: 5.118

6.  Algevir: An Expression System for Microalgae Based on Viral Vectors.

Authors:  Bernardo Bañuelos-Hernández; Elizabeth Monreal-Escalante; Omar González-Ortega; Carlos Angulo; Sergio Rosales-Mendoza
Journal:  Front Microbiol       Date:  2017-06-30       Impact factor: 5.640

Review 7.  The potential of plant systems to break the HIV-TB link.

Authors:  Peyman Habibi; Henry Daniell; Carlos Ricardo Soccol; Maria Fatima Grossi-de-Sa
Journal:  Plant Biotechnol J       Date:  2019-07-18       Impact factor: 9.803

Review 8.  Plant Platforms for Efficient Heterologous Protein Production.

Authors:  Siddhesh B Ghag; Vinayak S Adki; Thumballi R Ganapathi; Vishwas A Bapat
Journal:  Biotechnol Bioprocess Eng       Date:  2021-08-07       Impact factor: 2.836

Review 9.  Plants as Factories for Human Pharmaceuticals: Applications and Challenges.

Authors:  Jian Yao; Yunqi Weng; Alexia Dickey; Kevin Yueju Wang
Journal:  Int J Mol Sci       Date:  2015-12-02       Impact factor: 5.923

Review 10.  Virus-based pharmaceutical production in plants: an opportunity to reduce health problems in Africa.

Authors:  Pingdwende Kader Aziz Bamogo; Christophe Brugidou; Drissa Sérémé; Fidèle Tiendrébéogo; Florencia Wendkuuni Djigma; Jacques Simpore; Séverine Lacombe
Journal:  Virol J       Date:  2019-12-30       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.